Filed Under:Health Insurance, Medicare

Alzheimer's R&D funding should double, witness says

Alzheimer's disease plaque. (University of Pennsylvania School of Medicine photo/James Eberwine)
Alzheimer's disease plaque. (University of Pennsylvania School of Medicine photo/James Eberwine)

The growing cost of care for people with dementia could be as grave of a world health threat as AIDS or tuberculosis, and U.S. health research budget planners should remember that when allocating funding.

Witnesses representing people with Alzheimer's, drug companies, care providers and large employers made that case earlier this week at a hearing on dementia organized by the House Foreign Affairs global health subcommittee.

Featured Video

Most Recent Videos

Prospects not listening to voice mail? Arrange a phone date

Provided by LIFEHEALTHPRO

Redesigning your phone life is more important than finding the “best words” for a voice mail in today’s culture.

Behind the scenes with Vicki Gunvalson [VIDEO]

Provided by LIFEHEALTHPRO

In this exclusive interview, Vicki Gunvalson shares how she built a $15 million a year annuity business by planning for...

Regulator: Market may need to reinvent LTCI

Provided by LIFEHEALTHPRO

Cioppa says Maine's governor wants to spur the creation of better products.

Dementia: It's more than Alzheimer's

Provided by LIFEHEALTHPRO

An association calls for policymakers to remember lesser-known neurodegenerative conditions.

Related resources

More Resources

Comments

Power your business with up-to-the-minute insurance news, analysis, and best practices from LifeHealthPro Daily eNewsletter – FREE.

Power your business with LifeHealthPro Daily eNewsletter – FREE.

Enter a valid email address.
Close
Nichole Morford

Nichole Morford
Managing Editor

Thank you for subscribing to LifeHealthPro Daily!

Check Out More eNewsletters Now! Close

Advertisement. Closing in 15 seconds.